ClinicalTrials.gg
TerminatedNCT00727194Updated Sep 24, 2019Results posted

Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis

A Phase 2 interventional study of eculizumab and Placebo in Myasthenia Gravis, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 25 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Myasthenia Gravis by AstraZeneca — 8 open to participants now, 11 under way, 4 of them phase 3. Myasthenia Gravis · AstraZeneca.

Enrollment
9th of 13
14 · median 20
Started
2008
the only one that year
Phase 2
3 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies in Myasthenia Gravis by AstraZeneca, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2008, is one of 3 in phase 2, and was the 1st registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

8 of the 19 studies in Myasthenia Gravis by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myasthenia Gravis by AstraZeneca, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of patients with generalized myasthenia gravis despite treatment with various immunosuppressants, such as prednisone, methotrexate, Cellcept, cyclosporine, and cyclophosphamide, that are currently available.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generalized MG
  • MGFA Clinical Classification Class II, III or IVa.
  • QMG total score ≥12
  • Minimum score of two (2) in four (4) or more test items in the QMG
  • Able to give .
  • Have failed at least two after one year of treatment
  • A positive serologic test for binding anti-acetylcholine receptor Abs at Screening and one of the following a) history of abnormal neuromuscular transmission test demonstrated by single-fiber electromyography or repetitive nerve stimulation, or b) history of positive anticholinesterase test, eg, edrophonium chloride test, or c) patient has demonstrated improvement in MG signs on acetylcholinesterase inhibitors as assessed by treating physician.

Exclusion criteria

Exclusion Criteria:

  • History of thymoma or other neoplasms of the thymus.
  • History of thymectomy within 12 months prior to screening.
  • Pregnancy or lactation
  • Current or chronic use of plasmapheresis/plasma exchange
  • IVIG treatment within 8 weeks prior to screening.
  • Use of etanercept within 2 months prior to screening.
  • Use of rituximab (RITUXAN®) within 6 months prior to screening.
  • MGFA Class I, IVb, and V
  • Crisis or impending crisis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    1

    eculizumab

    Drug: eculizumab

  • Placebo comparator
    2

    Placebo

    Drug: Placebo

Interventions

  • eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses

    Also known as: Soliris

  • DrugPlacebo

    Placebo IV weekly for 4 doses then every two weeks for 7 doses

06

What researchers measure

Primary outcomes

  1. Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.

    The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG.

    Time frame: 16 weeks

Secondary outcomes

  1. Mean Change From Baseline in QMG Total Score

    The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The Myasthenia Gravis Foundation of America task force has recommended that the QMG score be used in prospective studies of therapy for MG. The QMG scoring system consists of 13 items. Each item is graded 0 to 3, with 3 being the most severe. The range of total QMG score is 0-39.

    Time frame: 16 weeks

  2. Change From Baseline in the MGFA Post-Intervention Status (PIS)

    The MGFA PIS is designed to assess the clinical state of MG patients at any time after treatment of MG is initiated. Change in status categories of Improved, Unchanged, Worse, Exacerbation, and Died of MG was to be assessed and recorded at every visit from Visits 3 to 24 (Weeks 1 to 16). Minimal manifestations were to be assessed at these visits.

    Time frame: 16 weeks

  3. Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)

    The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living (ADL) in MG patients. The 8 items of the MG-ADL were derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 - 24. MG-ADL was to be performed at every study visit. The recall period for MG-ADL was since the preceding study visit (1 or 2 weeks).

    Time frame: 16 weeks

  4. Change From Baseline in the QoL Instrument, SF-36.

    The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (physical functioning, role-physical, bodily pain, general health, mental health, role-emotional, social functioning and vitality) as well as psychometrically-based physical and mental health summary measures. It is a generic measure, as opposed to one that targets a specific age, disease or treatment group. The lower the score the more disability; the higher the score the less disability. Norm-based scoring involving a linear T-score transformation method was used so that scores for each of the health domain scales and component summary measures have a mean of 50 and a standard deviation of 10 based on the 1998 US general population. Thus, scores above and below 50 are above and below the average, respectively, in the 1998 US general.

    Time frame: 16 weeks

  5. Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.

    Change from Baseline in Forced Vital Capacity

    Time frame: 16 weeks

  6. Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.

    Change from Baseline in Negative Inspiratory Force. NIF is a measurement of respiratory muscle strength and ventilator reserve. NIF is represented by centimeters of water pressure (cmH2O). A normal NIF measurement is negative 60 cmH2O, or as 100% predicted value.

    Time frame: 16 weeks

  7. Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)

    The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.

    Time frame: 16 weeks

  8. Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)

    The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.

    Time frame: 16 weeks

07

Results

Posted Dec 12, 2016
Limitations and caveats
Small sample size limited ability to detect intercohort differences. Carryover effect from Treatment Period (TP) 1 warrants cautious interpretation of TP 2 data. Study terminated early; 13 patients received eculizumab or placebo in TP2.

Participant flow

There were 26 IRB/IEC-approved study sites. Patients were screened at 13 Institutional Review Board/Independent Ethics Committee approved study sites; and 14 patients were randomized at 8 sites.

Screening Period
Participant flow — Screening Period
MilestoneEculizumab to Placebo SequencePlacebo to Eculizumab SequenceNot Randomized/Screen Failures
Started7716
Completed770
Not completed0016
Withdrew: Low qmg scores006
Withdrew: Lacked achr antibodies005
Withdrew: Not stable on concomitant mg therapy002
Withdrew: Severe infections002
Withdrew: History of thymoma001
Treatment Period 1
Participant flow — Treatment Period 1
MilestoneEculizumab to Placebo SequencePlacebo to Eculizumab SequenceNot Randomized/Screen Failures
Started770
Completed770
Not completed000
Washout Period
Participant flow — Washout Period
MilestoneEculizumab to Placebo SequencePlacebo to Eculizumab SequenceNot Randomized/Screen Failures
Started770
Completed770
Not completed000
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneEculizumab to Placebo SequencePlacebo to Eculizumab SequenceNot Randomized/Screen Failures
Started660
Completed650
Not completed010
Withdrew: Lack of efficacy010

Outcome measures

PrimaryQuantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.

The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG.

Time frame:
16 weeks
Reported as:
Number · percentage of patients
Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.
percentage of patientsEculizumab Period 1Placebo Period 1
Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.8657
SecondaryMean Change From Baseline in QMG Total Score

The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The Myasthenia Gravis Foundation of America task force has recommended that the QMG score be used in prospective studies of therapy for MG. The QMG scoring system consists of 13 items. Each item is graded 0 to 3, with 3 being the most severe. The range of total QMG score is 0-39.

Time frame:
16 weeks
Reported as:
Mean · units on a scale
Mean Change From Baseline in QMG Total Score
units on a scaleEculizumab Period 1Placebo Period 1Eculizumab Both PeriodsPlacebo Both Periods
Mean Change From Baseline in QMG Total Score-7.43 ± 5.563-2.71 ± 4.855-7.92 ± 5.054-3.67 ± 4.008
Statistical analysis
  • Eculizumab Both Periods vs Placebo Both Periods · paired t-test · p = 0.0144 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -4.25 · 95% CI -7.45 to -1.05
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.1170 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -4.71 · 95% CI -10.80 to 1.37
SecondaryChange From Baseline in the MGFA Post-Intervention Status (PIS)

The MGFA PIS is designed to assess the clinical state of MG patients at any time after treatment of MG is initiated. Change in status categories of Improved, Unchanged, Worse, Exacerbation, and Died of MG was to be assessed and recorded at every visit from Visits 3 to 24 (Weeks 1 to 16). Minimal manifestations were to be assessed at these visits.

Time frame:
16 weeks
Reported as:
Number · participants
Change From Baseline in the MGFA Post-Intervention Status (PIS)
participantsEculizumab Period 1Placebo Period 1Eculizumab Period 2Placebo Period 2
Improved5662
Unchanged2104
Worse0000
Exacerbation0000
Died of MG0000
Statistical analysis
  • Eculizumab Period 1 vs Placebo Period 1 · Chi-squared · p = 1.0000 (No multiple comparisons or multiplicity adjustments were conducted.)
  • Eculizumab Period 2 vs Placebo Period 2 · Chi-squared · p = 0.0606 (No multiple comparisons or multiplicity adjustments were conducted.)
SecondaryChange From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)

The MG-ADL is an 8-point questionnaire that focuses on relevant symptoms and functional performance of activities of daily living (ADL) in MG patients. The 8 items of the MG-ADL were derived from symptom-based components of the original 13-item QMG to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory (1 item), and gross motor or limb (2 items) impairment related to effects from MG. In this functional status instrument, each response is graded 0 (normal) to 3 (most severe). The range of total MG-ADL score is 0 - 24. MG-ADL was to be performed at every study visit. The recall period for MG-ADL was since the preceding study visit (1 or 2 weeks).

Time frame:
16 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)
units on a scaleEculizumab Period 1Placebo Period 1Eculizumab Both PeriodsPlacebo Both Periods
Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)4.29 ± 1.7997.86 ± 3.7165.42 ± 3.3157.00 ± 3.464
Statistical analysis
  • Eculizumab Both Periods vs Placebo Both Periods · paired t-test · p = 0.1873 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -1.58 · 95% CI -4.08 to 0.91
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.0410 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -3.57 · 95% CI -6.97 to -0.17
SecondaryChange From Baseline in the QoL Instrument, SF-36.

The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (physical functioning, role-physical, bodily pain, general health, mental health, role-emotional, social functioning and vitality) as well as psychometrically-based physical and mental health summary measures. It is a generic measure, as opposed to one that targets a specific age, disease or treatment group. The lower the score the more disability; the higher the score the less disability. Norm-based scoring involving a linear T-score transformation method was used so that scores for each of the health domain scales and component summary measures have a mean of 50 and a standard deviation of 10 based on the 1998 US general population. Thus, scores above and below 50 are above and below the average, respectively, in the 1998 US general.

Time frame:
16 weeks
Reported as:
Mean · units on a scale
Change From Baseline in the QoL Instrument, SF-36.
units on a scaleEculizumab Period 1Placebo Period 1Eculizumab Both PeriodsPlacebo Both Periods
Physical Functioning (Last Visit)56.43 ± 29.25564.29 ± 24.05457.92 ± 26.92157.08 ± 27.507
Role Physical (Last Visit)61.61 ± 38.60068.75 ± 25.76964.06 ± 31.77160.94 ± 27.324
Bodily Pain (Last Visit)60.00 ± 24.23574.86 ± 20.65166.75 ± 22.51176.17 ± 15.689
General Health (Last Visit)47.86 ± 16.99440.43 ± 23.20144.67 ± 16.26737.50 ± 19.365
Vitality (Last Visit)50.00 ± 23.93652.68 ± 15.67053.13 ± 19.31048.96 ± 18.238
Social Functioning (Last Visit)66.07 ± 25.73382.14 ± 17.46666.67 ± 24.03478.13 ± 17.778
Role Emotional (Last Visit)77.38 ± 36.23371.43 ± 29.60370.83 ± 34.54282.64 ± 25.981
Mental Health (Last Visit)76.43 ± 17.72858.57 ± 25.28469.17 ± 20.54268.75 ± 23.270
Physical Component Score (Last Visit)38.73 ± 10.23544.97 ± 7.72141.40 ± 8.59140.32 ± 10.025
Mental Component Score (Last Visit)49.50 ± 12.06643.95 ± 12.53046.11 ± 12.59649.03 ± 11.476
Statistical analysis
  • Eculizumab Both Periods vs Placebo Both Periods · paired t-test · p = 0.9190 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 0.83 · 95% CI -16.94 to 18.60
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.5931 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -7.86 · 95% CI -39.05 to 23.33
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.7319 (No multiple comparisons or multiplicity adjustments were conducted.) · Median difference (net): 3.13 · 95% CI -16.64 to 22.89
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.6910 (No multiple comparisons or multiplicity adjustments were conducted.) · Median difference (net): -7.14 · 95% CI -45.36 to 31.08
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.1311 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -9.42 · 95% CI -22.18 to 3.34
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.2406 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -14.86 · 95% CI -41.08 to 11.36
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.0578 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 7.17 · 95% CI -0.29 to 14.62
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.5073 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 7.43 · 95% CI -16.26 to 31.11
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.2474 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 4.17 · 95% CI -3.39 to 11.72
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.8085 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -2.68 · 95% CI -26.24 to 20.88
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.0716 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -11.46 · 95% CI -24.13 to 1.21
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.1966 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -16.07 · 95% CI -41.68 to 9.54
  • Eculizumab Both Periods vs Placebo Both Periods · paired t-test · p = 0.1701 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -11.81 · 95% CI -29.60 to 5.99
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.7422 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 5.95 · 95% CI -32.58 to 44.48
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.9007 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 0.42 · 95% CI -6.83 to 7.67
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.1519 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 17.86 · 95% CI -7.57 to 43.29
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.6807 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 1.07 · 95% CI -4.57 to 6.72
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.2226 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -6.23 · 95% CI -16.79 to 4.32
  • Eculizumab Both Periods vs Placebo Both Periods · Paired t-test · p = 0.1505 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): -2.92 · 95% CI -7.10 to 1.26
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.4151 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 5.55 · 95% CI -8.77 to 19.87
SecondaryChange From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.

Change from Baseline in Forced Vital Capacity

Time frame:
16 weeks
Reported as:
Mean · percentage of predicted
Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.
percentage of predictedEculizumab Period 1Placebo Period 1Eculizumab Both PeriodsPlacebo Both Periods
Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.76.43 ± 15.32887.00 ± 23.54480.00 ± 14.89476.75 ± 23.152
Statistical analysis
  • Eculizumab Both Periods vs Placebo Both Periods · paired t-test · p = 0.3377 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 3.25 · 95% CI -3.94 to 10.44
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.3391 (No multiple comparisons or multiplicity adjustments were conducted.) · Median difference (net): -10.57 · 95% CI -33.71 to 12.56
  • Eculizumab Both Periods vs Placebo Both Periods · paired t test · p = 1.0000 (No multiple comparisons or multiplicity adjustments were conducted.) · Mean difference (net): 0.00 · 95% CI -4.35 to 4.35
  • Eculizumab Period 1 vs Placebo Period 1 · t-test, 2 sided · p = 0.2292 (No multiple comparisons or multiplicity adjustments were conducted.) · Median difference (final values): -6.57 · 95% CI -17.87 to 4.73
SecondaryChange From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.

Change from Baseline in Negative Inspiratory Force. NIF is a measurement of respiratory muscle strength and ventilator reserve. NIF is represented by centimeters of water pressure (cmH2O). A normal NIF measurement is negative 60 cmH2O, or as 100% predicted value.

Time frame:
16 weeks
Reported as:
Mean · percentage of predicted
Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.
percentage of predictedEculizumab Period 1Placebo Period 1Eculizumab Both PeriodsPlacebo Both Periods
Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.92.43 ± 13.46499.00 ± 2.64693.50 ± 12.08793.50 ± 12.042
SecondaryChange From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)

The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.

Time frame:
16 weeks
Reported as:
Mean · units on a scale
Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)
units on a scaleEculizumabPlacebo
Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)-0.71 ± 1.113-0.29 ± 0.488
SecondaryChange From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)

The QMG scoring system is considered to be an objective evaluation of muscle strength based on quantitative testing of sentinel muscle groups. The MGFA task force has recommended that the QMG score be used in prospective studies of therapy for MG. All individual QMG items are scored 0 to 3, with 3 being the most severe. Negative values imply an improvement in QMG Item Score.

Time frame:
16 weeks
Reported as:
Mean · units on a scale
Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)
units on a scaleEculizumabPlacebo
Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)-1.00 ± 1.155-0.5 ± 1.000

Adverse events

Collected over 46 weeks (Screening Period [up to 4 weeks], Treatment Period 1 [16 weeks], Washout Period [5 weeks], Treatment Period 2 [16 weeks], Follow-up Period [5 weeks]) for adverse events (AEs); 42 weeks for treatment emergent AEs (TEAEs).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/13 (7.7%)11/13 (84.6%)
Eculizumab—1/13 (7.7%)13/13 (100%)
Most frequent serious events
Most frequent serious events
EventPlaceboEculizumab
Myasthenia GravisNervous system disorders0/131/13
Myasthenia Gravis CrisisNervous system disorders1/130/13
Most frequent other events
Showing 10 of 94
Most frequent other events
EventPlaceboEculizumab
NauseaBlood and lymphatic system disorders2/134/13
Back PainMusculoskeletal and connective tissue disorders1/134/13
HeadacheNervous system disorders4/133/13
NasopharyngitisInfections and infestations2/133/13
MyalgiaMusculoskeletal and connective tissue disorders2/133/13
Neck PainMusculoskeletal and connective tissue disorders1/133/13
CoughRespiratory, thoracic and mediastinal disorders0/133/13
ConstipationGastrointestinal disorders0/132/13
FatigueGeneral disorders1/132/13
InfluenzaInfections and infestations0/132/13

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study
Mean49 ± 14
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female8
Male6
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Overall Study
Caucasian11
Hispanic2
Black1
Region of Enrollment
Region of Enrollment(participants)Overall Study
United States13
United Kingdom1
Myasthenia Gravis Foundation of America (MGFA) classification at Screening
Myasthenia Gravis Foundation of America (MGFA) classification at Screening(participants)Overall Study
IIa2
IIb2
IIIa8
IVa2
Number of MG crisis/exacerbation prior to Screening
Number of MG crisis/exacerbation prior to Screening(Events)Overall Study
Mean5 ± 6
Prednisone use at Screening
Prednisone use at Screening(participants)Overall Study
Prednisone use7
No prednisone use7
Immunosuppression therapy other than prednisone at Screening
Immunosuppression therapy other than prednisone at Screening(participants)Overall Study
Yes7
No7

3 further baseline measures are reported on the registry.

08

Study locations

25 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • University of California, Irvine
    Orange, California 92868, United States
  • University of California - Davis
    Sacramento, California 95817, United States
  • University of Florida & Shands Neuroscience Institute
    Jacksonville, Florida 32209, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Wishard Hospital
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Johns Hopkins University School of Medicine
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Caritas St. Elizabeths' Medical Center
    Boston, Massachusetts 02135, United States
  • Wayne State University
    Detroit, Michigan 48201, United States
  • Mount Sinai School of Medicine
    New York, New York 10029-6574, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599-1651, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • University Hospitals - Case Medical Center
    Cleveland, Ohio 44106-5098, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • The Warren Alpert Medical School of Brown University
    Providence, Rhode Island 02905, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • University of Texas Southwestern Medical School
    Dallas, Texas 75390, United States
  • The University of Vermont College of Medicine
    Burlington, Vermont 05405, United States
  • University of Virginia
    Charlottesville, Virginia 22908-0394, United States
  • The Northern Alberta Clinical trials and Research Centre
    Edmonton, Alberta, Canada
  • Institute of Neurological Sciences, Department of Neurology, Southern General Hospital,
    Glasgow, United Kingdom
  • Institute of Neurology
    London, United Kingdom
  • Department of Clinical Neurology, West Wing, John Radcliffe Hospital
    Oxford, United Kingdom
09

References and documents

Publications

  • Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30. PubMed 23512355 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Mar 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 5 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2008
First posted
Aug 1, 2008
Start
Oct 2008
Primary completionActual
Mar 2011
CompletionActual
Jul 2011
Results first posted
Dec 12, 2016
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00727194
Responsible party
Sponsor
First posted
Aug 1, 2008
Start date
Oct 2008
Primary completion
Mar 2011
Completion
Jul 2011
Results posted
Dec 12, 2016
Last update
Sep 24, 2019

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eculizumab

Start the discussion